REPUBLIC HC plans to invest in Langgu Bio through capital increase and share expansion
REPUBLIC HC announced that it has signed a letter of intent for an investment agreement with Langgu Bio, planning to invest through capital increase and share expansion. The investment amount and shareholding ratio will be determined in the formal agreement. Langgu Bio's personalized DC vaccine technology has been approved for clinical treatment, marking its transformation into a profitable enterprise. This move will help REPUBLIC HC expand into the Southeast Asian and Greater China markets, enhance investment returns, and create new business opportunities
According to the Zhitong Finance APP, REPUBLIC HC (08357) announced that after in-depth and multi-dimensional business discussions with Shenzhen Ronghui Renhe, the company believes that Chengdu Langgu Biotechnology Co., Ltd. (Langgu Bio), another company controlled by Mr. Ding Xing, the ultimate beneficial owner of Shenzhen Ronghui Renhe, has significant investment value. Accordingly, the company's board of directors announced that on April 11, 2025 (after trading hours), the company entered into a letter of intent for investment with Langgu Bio, and both parties agreed that the company or its subsidiaries would invest in Langgu Bio through capital increase and share expansion, with the actual investment amount and the company's shareholding ratio in Langgu Bio to be determined when both parties sign the formal share subscription agreement.
Considering Langgu Bio's R&D background and business development status; and the advanced technology of personalized DC vaccine treatment for malignant tumors held by Langgu Bio, which was approved in February 2025 by the Hainan Boao Lecheng International Medical Tourism Pilot Zone Medical Products Administration as one of the first batch of biomedical new technology transformation applications for clinical treatment, this indicates that Langgu Bio is transforming from a continuously R&D-oriented enterprise into a profitable enterprise that can publicly use technology in designated hospitals and generate revenue. The board of directors believes that this capital increase has very significant strategic significance for the company, as it will not only help the company leverage advanced technology to expand into the Southeast Asian market and open up the Greater China market but also enhance the company's investment returns, bringing new market opportunities and commercial value for both parties
